Axon Enterprise (NASDAQ:AXON) CFO Brittany Bagley Sells 870 Shares of Stock

Axon Enterprise, Inc (NASDAQ:AXON) CFO Brittany Bagley sold 870 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $773.25, for a total value of $672,727.50. Following the completion of the sale, the chief financial officer directly owned 113,022 shares of the company’s stock, valued at $87,394,261.50. This trade represents a 0.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Axon Enterprise Trading Up 0.6%

Shares of Axon Enterprise stock opened at $760.79 on Tuesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. Axon Enterprise, Inc has a 52 week low of $376.53 and a 52 week high of $885.91. The stock has a 50 day moving average price of $760.28 and a two-hundred day moving average price of $690.00. The stock has a market capitalization of $59.73 billion, a PE ratio of 187.85, a price-to-earnings-growth ratio of 27.75 and a beta of 1.40.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The firm had revenue of $668.54 million during the quarter, compared to analysts’ expectations of $641.77 million. During the same quarter last year, the firm posted $1.20 earnings per share. The company’s revenue for the quarter was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on AXON. Morgan Stanley set a $885.00 target price on Axon Enterprise and gave the company an “overweight” rating in a research report on Friday, July 11th. Needham & Company LLC set a $870.00 target price on Axon Enterprise and gave the company a “buy” rating in a research report on Tuesday, August 5th. Northland Securities set a $800.00 target price on Axon Enterprise in a research report on Tuesday, August 5th. Bank of America lifted their target price on Axon Enterprise from $895.00 to $1,000.00 and gave the company a “buy” rating in a research report on Wednesday, August 6th. Finally, Craig Hallum raised Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 target price on the stock in a research report on Tuesday, August 5th. Thirteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Axon Enterprise has an average rating of “Moderate Buy” and an average target price of $837.69.

Institutional Trading of Axon Enterprise

A number of hedge funds have recently bought and sold shares of AXON. Westside Investment Management Inc. raised its holdings in Axon Enterprise by 4.8% during the second quarter. Westside Investment Management Inc. now owns 283 shares of the biotechnology company’s stock valued at $225,000 after acquiring an additional 13 shares during the period. CVA Family Office LLC grew its position in shares of Axon Enterprise by 26.9% during the second quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 14 shares in the last quarter. Newbridge Financial Services Group Inc. grew its position in shares of Axon Enterprise by 2.8% during the second quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock valued at $421,000 after purchasing an additional 14 shares in the last quarter. Evergreen Capital Management LLC grew its position in shares of Axon Enterprise by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 15 shares in the last quarter. Finally, LaSalle St. Investment Advisors LLC grew its position in shares of Axon Enterprise by 2.1% during the first quarter. LaSalle St. Investment Advisors LLC now owns 777 shares of the biotechnology company’s stock valued at $408,000 after purchasing an additional 16 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.